News
Novavax shares declined after a Wall Street Journal report that federal regulators are asking the company to complete an additional randomized clinical trial on its Covid-19 vaccine, according to ...
Novavax (NasdaqGS:NVAX) recently announced preliminary results from its SHIELD-Utah study, showcasing the Novavax COVID-19 vaccine's effectiveness and reduced side effects compared to a competitor's ...
The FDA is considering the approval of the Novavax COVID-19 booster after delays amid controversy over its non-mRNA design.
Novavax (NASDAQ: NVAX) shares declined 6% following a report from the Wall Street Journal that said federal regulators are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results